Ciprofloxacin Overview
Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic indicated primarily for complicated urinary tract infections, certain respiratory infections, skin/soft tissue infections, bone/joint infections, and specific gastrointestinal infections, but should NOT be used as first-line therapy for most conditions due to resistance concerns and adverse event risks, particularly musculoskeletal toxicity in children. 1
FDA-Approved Indications
Adult Patients
The FDA-approved indications include 1:
- Urinary tract infections (UTIs) caused by susceptible organisms including E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and others
- Acute uncomplicated cystitis in females
- Chronic bacterial prostatitis
- Lower respiratory tract infections (though NOT first-choice for S. pneumoniae pneumonia)
- Acute sinusitis
- Skin and skin structure infections
- Bone and joint infections
- Complicated intra-abdominal infections (combined with metronidazole)
- Infectious diarrhea (enterotoxigenic E. coli, Campylobacter, Shigella)
- Typhoid fever
- Uncomplicated gonorrhea
Pediatric Patients (1-17 years)
Ciprofloxacin is NOT a first-line agent in children due to increased adverse events, particularly arthropathy 1. The only FDA-approved pediatric indication is:
- Complicated UTIs and pyelonephritis due to E. coli when other agents are inappropriate 1
Important caveat: Pediatric guidelines support ciprofloxacin use only when typically recommended agents are unsuitable based on susceptibility, allergy, or adverse-event history 2. Additional off-label uses in children include multidrug-resistant tuberculosis and Pseudomonas infections when no alternatives exist 2.
Dosing Recommendations
Based on FDA labeling 1:
- Uncomplicated UTI: 250 mg twice daily
- Complicated UTI/Pyelonephritis: 500 mg twice daily
- Respiratory tract infections: 500-750 mg twice daily
- Skin/soft tissue infections: 500-750 mg twice daily
- Bone/joint infections: 500-750 mg twice daily
- Acute uncomplicated gonorrhea: 250-500 mg single dose
- Meningococcal prophylaxis: 500 mg single dose (adults); 20 mg/kg single dose (children >1 month) 2
Duration: Typically 7-14 days depending on infection type; 10-21 days for complicated infections 1
Critical administration note: Discontinue enteral feeding 2 hours before to 6 hours after ciprofloxacin administration due to interaction with polyvalent cations that impair absorption 3.
Contraindications
Absolute contraindications 1:
- History of hypersensitivity to ciprofloxacin or any quinolone
- Concomitant use with tizanidine (mandatory contraindication)
- Age ≤18 years (relative contraindication except for approved indications) 4
Adverse Effects
Common Adverse Events (>1%)
From FDA data on 49,038 patients 1:
- Gastrointestinal (most common): Nausea (2.5%), diarrhea (1.6%), vomiting (1%), abdominal discomfort
- Hepatic: Abnormal liver function tests (1.3%)
- Dermatologic: Rash (1%), pruritus, photosensitivity
- CNS: Dizziness, headache (1-4% of patients) 5
Overall adverse event rate: 10-16% depending on dosage, with most events mild-to-moderate 1, 6
Serious Adverse Events (<1%)
Musculoskeletal toxicity is the most concerning, particularly in pediatrics:
- Arthropathy/tendinitis: 3.97% in pediatric trials 1
- Arthralgia and joint abnormalities: 9.3% in children vs 6% with comparators within 6 weeks 1
- Most events resolved within 30 days of treatment cessation 1
Severe cutaneous reactions 7:
- Toxic epidermal necrolysis
- Stevens-Johnson syndrome
- Fixed drug eruptions
- DRESS syndrome
- Acute generalized exanthematous pustulosis
Other serious events 1:
- QTc prolongation (2.65%)
- Dysglycemia: Hypoglycemia (1.32%), hyperglycemia (0.66%)
- CNS: Seizures (especially with concurrent theophylline), tremor, confusion
- Pseudomembranous colitis
- Interstitial nephritis
Drug Interactions
Significant interactions requiring monitoring 4:
- Theophylline: Increases theophylline levels, risk of seizures
- NSAIDs (ibuprofen 31.1%): Increased CNS stimulation risk
- Antacids/polyvalent cations (16.6%): Decreased ciprofloxacin absorption
- Corticosteroids (prednisolone 7.9%): Increased tendon rupture risk
- QT-prolonging drugs: Additive cardiac effects
Clinical Practice Pitfalls
The most critical error is using ciprofloxacin as first-line therapy when better alternatives exist. A Norwegian hospital study found 92% of ciprofloxacin prescriptions were inconsistent with national guidelines 8.
Key principles:
- Reserve ciprofloxacin for infections where susceptibility data, allergy history, or treatment failure necessitate its use 2
- Never use as first-line for S. pneumoniae pneumonia 1
- Avoid in children unless no suitable alternatives exist 2, 1
- Monitor for musculoskeletal symptoms, especially in children and elderly
- Discontinue immediately if tendinitis, severe rash, or CNS symptoms develop
- Ensure proper spacing from enteral feeds and polyvalent cations
Management of adverse reactions: Complete cessation of ciprofloxacin, followed by supportive care with corticosteroids (oral/topical), emollients, and moisturizers for cutaneous reactions 7.